R&D News | pharmaphorum

News

MeiraGTx plans to take Parkinson's gene therapy into phase 3

Armed with data from a small phase 1/2 bridging study, MeiraGTx is preparing to take its gene therapy for Parkinson's disease into a pivotal trial.

News

Pfizer sticks $1.5bn on Triana's molecular glue tech

Big pharma's interest in using protein degradation as a therapeutic strategy continues with a wide-ranging deal between Pfizer and US biotech Triana Biomedicines that could be worth $1.5 bi

News

Transgene cervical cancer shot misses the mark in phase 2

Transgene's therapeutic vaccine for cervical and anogenital cancers has failed a phase 2 trial, but an efficacy signal warrants further study

News

Lundbeck drops in on epilepsy drug with $2.6bn Longboard bid

Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster.

News

Lilly pledges £279m to UK for biotech hub and obesity plan

Eli Lilly has said it is prepared to invest £279 million ($364 million) in the UK and work with the government to tackle serious public health challenges, including obesity.

News

Africa CDC Director General Dr Jean Kaseya

CEPI-backed trial of Rift Valley fever jab starts in Kenya

A promising vaccine candidate for Rift Valley fever (RVF) has been advanced into a phase 2 trial in Kenya, the first time that a shot has reached this stage of development in a country wher

MeiraGTx plans to take Parkinson's gene therapy into phase 3

Pfizer sticks $1.5bn on Triana's molecular glue tech

Transgene cervical cancer shot misses the mark in phase 2

Lundbeck drops in on epilepsy drug with $2.6bn Longboard bid

Lilly pledges £279m to UK for biotech hub and obesity plan

CEPI-backed trial of Rift Valley fever jab starts in Kenya

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks